NewAmsterdam Pharma's European approval and advanced obicetrapib trials create substantial commercial potential, but unproven recurring royalties, persistent cash burn, and cardiovascular outcomes uncertainty constrain the investment case.
Sell-rated reports
287 tickers rated SellAlgonquin's regulated utility restructuring offers a path toward more predictable earnings and improved capital discipline, but elevated debt, wildfire costs, and weak free cash flow continue to constrain shareholder returns.
Core Scientific offers exceptional AI data center revenue growth backed by substantial contracted capacity, but heavy capital spending, leverage and customer concentration threaten sustainable shareholder returns.
IREN offers substantial AI cloud growth through major customer contracts and power-connected infrastructure, but heavy capital spending, shareholder dilution, and uncertain free cash flow threaten investment returns.
Viasat could benefit from expanding defense demand and monetizing its newly deployed satellite capacity, but weak capital returns, commercial connectivity competition, and substantial leverage undermine the current investment case.
Caris Life Sciences offers long-term growth through precision oncology and proprietary genomic data, but deteriorating cash conversion, rising operating costs and demanding valuation undermine its near-term investment appeal.
TransAlta could benefit from contracted gas generation and rising data-center electricity demand, but declining free cash flow, substantial leverage and elevated historical valuation limit its current investment appeal.
Denali's validated blood-brain barrier platform and accelerating AVLAYAH launch offer significant long-term growth potential, but persistent cash burn, concentrated revenue, and demanding execution expectations constrain near-term investment appeal.
Coupang's powerful Korean fulfillment network and international expansion offer long-term growth potential, but weakened margins, negative free cash flow, and regulatory liabilities undermine near-term investment returns.
Vornado's premium Manhattan portfolio and improving leasing economics offer turnaround potential, but high leverage, redevelopment spending, and an elevated historical valuation limit the margin of safety.
Life Time's premium athletic clubs offer durable membership growth and improving operating leverage, but its demanding valuation, heavy development spending, and negative free cash flow constrain shareholder returns.
UFP Industries has strong liquidity, valuable manufacturing franchises, and acquisition-driven recovery potential, but persistent freight inflation, weak capital returns, and demanding normalized cash-flow expectations limit near-term upside.